Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-2-26
pubmed:abstractText
Circulating tumor cells (CTCs) cannot be readily detected with currently available methods in the majority of patients with prostate cancer. Telomerase activation, one of the major immortalization events, is found in most cases of prostate cancer. We attempted to develop a method using telomerase activity to isolate CTCs in patients with prostate cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
518-21
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17322541-Adult, pubmed-meshheading:17322541-Case-Control Studies, pubmed-meshheading:17322541-Diatrizoate, pubmed-meshheading:17322541-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:17322541-Ficoll, pubmed-meshheading:17322541-Gene Expression Regulation, Enzymologic, pubmed-meshheading:17322541-Gene Expression Regulation, Neoplastic, pubmed-meshheading:17322541-Humans, pubmed-meshheading:17322541-Immunomagnetic Separation, pubmed-meshheading:17322541-Male, pubmed-meshheading:17322541-Middle Aged, pubmed-meshheading:17322541-Neoplastic Cells, Circulating, pubmed-meshheading:17322541-Polymerase Chain Reaction, pubmed-meshheading:17322541-Prognosis, pubmed-meshheading:17322541-Prostate-Specific Antigen, pubmed-meshheading:17322541-Prostatic Neoplasms, pubmed-meshheading:17322541-Telomerase, pubmed-meshheading:17322541-Treatment Outcome, pubmed-meshheading:17322541-Tumor Markers, Biological
pubmed:year
2007
pubmed:articleTitle
High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.
pubmed:affiliation
Department of Medicine, Institut Gustave Roussy, Villejuif, France. fizazi@igr.fr
pubmed:publicationType
Journal Article